- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02345278
SUBLIVAC FIX Mite Mixture Dose Tolerability Study (DTS)
A Randomized, Double-blind, Placebo-controlled Study to Determine Tolerability and Safety of Different Dosages of SUBLIVAC FIX Mite Mixture in Patients With Allergic Rhinitis / Rhinoconjunctivitis Caused by House Dust Mites
Allergic rhinitis/rhinoconjunctivitis is a symptomatic disorder of the nose induced by an immunoglobulin E (IgE) mediated inflammatory response. Treatment may involve pharmacotherapy and specific immunotherapy (IT). IT represents the only treatment that might alter the natural course of the disease. The amount of administered allergen is crucial for both efficacy and safety of specific IT. SUBLIVAC FIX Mite mixture is a preparation for sublingual IT (SLIT) and is indicated for the treatment of allergic disorders such as allergic rhinitis and rhinoconjunctivitis, caused by sensitisation to house dust mite (HDM) allergens.
According to the European Medicines Agency Guideline on the clinical development of products for specific IT for the treatment of allergic diseases, products should be tested at different dosages to provide preliminary data on safety and tolerability with regard to the maximum tolerated dose and suitable dose escalation scheme. This trial is designed to investigate the tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, D-10117
- Charite Universitatsmedizin Berlin, Allergiezentrum
-
Berlin, Germany, D-13057
- Praxis Dr.med.Elke Hippke
-
Chemnitz, Germany, D-09130
- HNO-Heilkunde Praxis
-
Dresden, Germany, D-01139
- HNO und Allergologie Praxis
-
Duisburg, Germany, D-47051
- HNO-Praxis Dr. Uta Thieme
-
Dusseldorf, Germany, D-40225
- Universitatsklinikum Dusseldorf, Department Dermatology
-
Gottingen, Germany, D-37073
- HNO Praxis Gottingen
-
Heidelberg, Germany, D-69126
- HNO Gemeinschaftspraxis
-
Heidelberg, Germany, D-69120
- HNO Praxis am Neckar
-
Wolmirstedt, Germany, D-39326
- Dr.med. Ulrich Neumann Praxis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Male or female patients, age ≥ 18 ≤ 60 years
- Patients with allergic rhinitis or rhinoconjunctivitis induced by HDM for at least 1 year, with or without concomitant at least partly controlled asthma
- Patients with a history of concomitant asthma should have a FEV1 > 70% (of predicted value) at inclusion. Patients without a history of asthma should have a FEV1 > 70% or a PEF > 80% (of predicted value)
- Positive SPT to HDM D. pter or D. far (mean wheal diameter ≥ 3 mm compared to negative control; negative control should be negative; histamine control should be positive (mean wheal diameter ≥ 3 mm) at screening
- Allergen specific serum IgE (ssIgE) level in serum for HDM D. pter or D. far (> 0.7 U/ml), assessed at screening
Exclusion Criteria:
- Patients with concomitant sensitization i.e. positive SPT (mean wheal diameter ≥ 3 mm compared to negative control; negative control should be negative; histamine control should be positive (mean wheal diameter ≥ 3 mm) who are expected to have clinically relevant symptoms during the treatment period
- Patients sensitized and symptomatic to pets who are regularly exposed to pets
- Completed allergen-specific immunotherapy (SCIT or SLIT) with HDM within the last 5 years
- Completed unsuccessful allergen-specific immunotherapy (SCIT or SLIT) within the last 5 years
- Allergen-specific immunotherapy (SCIT or SLIT) with other allergens than HDM during the study period
- Any other vaccination one week before start of treatment and during the up-dosing phase
- Any anti-IgE therapy within the last 6 months prior to inclusion and during study
- Active inflammatory disease in the mouth (e.g periodontitis, oral mucosal lichen planus)
- Known hypersensitivity to any of the excipients (i.e. Disodium phosphate dihydrate, Sodium dihydrogen phosphate dihydrate, Aminocaproic acid, Glycerol, Peppermint oil, Caramel Colorant) of SLIT solution
- Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
- Active malignancies or any malignant disease in the last 5 years
- A chronic or acute disease that in the opinion of the investigator might place the patient at an additional risk, including but not limited to the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine disorders, clinically significant renal or hepatic diseases, or haematological disorders
- Diseases with a contra-indication for the use of adrenaline (e.g. hyperthyroidism, glaucoma)
- Use of systemic corticosteroids 4 weeks before start treatment
- Treatment with systemic or local beta-blockers
- Clinically significant chronic sinusitis or ocular infection
- Participation in a clinical study with a new investigational drug within the last 3 months or a biological within the last 6 months prior to the study or during the study
- Pregnancy, lactation or inadequate contraceptive measures (acceptable forms of birth control include Intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections) or condom combined with a diaphragm including spermicidal cream). Also acceptable for women is surgical sterilization (removal of the uterus or ovaries or tubal ligation ("tied tubes")), if they are postmenopausal (12 consecutive months without a period) for at least 2 years, or having no sexual relationship with a man.
- Alcohol, drug, or medication abuse within the past year and during the study
- Any lack of co-operation or compliance
- Severe psychiatric, psychological, or neurological disorders
- Patients who are employees of the department or study site; 1st grade relatives, partners of the investigator, or patients who are dependent on the sponsor
- Any physical or mental condition that precludes administration of allergen-specific immunotherapy, compliance or participation in a trial
- Patients who are placed in an institution due to governmental or judicial directive
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
once daily sublingual administration for 1 month
|
Study medication will be taken sublingually once a day.
Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached.
Drops should be kept under the tongue for 2-3 minutes before swallowing.
After reaching the maintenance dose patients will be treated up to 1 month.
|
Active Comparator: SUBLIVAC FIX Mite mixture 10,000 AU/mL
once daily sublingual administration for 1 month
|
Study medication will be taken sublingually once a day.
Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached.
Drops should be kept under the tongue for 2-3 minutes before swallowing.
After reaching the maintenance dose patients will be treated up to 1 month.
|
Active Comparator: SUBLIVAC FIX Mite mixture 25,000 AU/mL
once daily sublingual administration for 1 month
|
Study medication will be taken sublingually once a day.
Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached.
Drops should be kept under the tongue for 2-3 minutes before swallowing.
After reaching the maintenance dose patients will be treated up to 1 month.
|
Active Comparator: SUBLIVAC FIX Mite mixture 50,000 AU/mL
once daily sublingual administration for 1 month
|
Study medication will be taken sublingually once a day.
Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached.
Drops should be kept under the tongue for 2-3 minutes before swallowing.
After reaching the maintenance dose patients will be treated up to 1 month.
|
Active Comparator: SUBLIVAC FIX Mite mixture 100,000 AU/mL
once daily sublingual administration for 1 month
|
Study medication will be taken sublingually once a day.
Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached.
Drops should be kept under the tongue for 2-3 minutes before swallowing.
After reaching the maintenance dose patients will be treated up to 1 month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of SUBLIVAC FIX Mite mixture (assessed by number and severity of local and systemic reactions)
Time Frame: 1 month treatment
|
Safety and tolerability of different dosages of SUBLIVAC FIX Mite mixture compared to placebo assessed by number and severity of local and systemic reactions.
|
1 month treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 1 month treatment
|
Safety of different dosages of SUBLIVAC FIX Mite mixture compared to placebo assessed by number and severity of Adverse Events
|
1 month treatment
|
Clinical and laboratory parameters (Safety of different dosages of SUBLIVAC FIX Mite mixture)
Time Frame: 1 month treatment
|
Safety of different dosages of SUBLIVAC FIX Mite mixture compared to placebo assessed by clinical and laboratory parameters
|
1 month treatment
|
Changes in immunoglobulin levels ((IgE, IgG, IgG4)
Time Frame: 1 month
|
Changes in serum specific immunoglobulin levels (IgE, IgG, IgG4) after 1 month of treatment with different dosages of SUBLIVAC FIX Mite mixture compared to placebo
|
1 month
|
Proportion of patients reaching maintenance dose within 10 days
Time Frame: 10 days
|
Proportions of patients in the different treatment groups reaching maintenance dose within 10 days
|
10 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Margitta Worm, Prof.Dr.med., Allergie-Centrum-Charité
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SM/0044
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on House Dust Mite Allergy
-
ALK-Abelló A/SCompletedHouse Dust Mite AllergyFrance
-
Allergopharma GmbH & Co. KGCompletedHouse Dust Mite AllergyGermany
-
Universitas AirlanggaNot yet recruiting
-
ASIT Biotech S.A.CompletedHouse Dust Mite AllergyGermany
-
Circassia LimitedAdiga Life Sciences, Inc.; Inflamax Research IncorporatedCompletedRhinoconjunctivitis | House Dust Mite Allergy
-
Probelte Pharma S.L.U.RecruitingHouse Dust Mite AllergySpain
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic RhinoconjunctivitisSwitzerland
-
T-Balance Therapeutics GmbHCompletedAllergic Asthma | Allergy to House Dust MiteGermany
-
Johann Wolfgang Goethe University HospitalCompletedHouse Dust Mite Allergy | Bronchial HyperresponsivenessGermany
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States